Oral silymarin for chronic hepatitis C - A retrospective analysis comparing three dose regimens

European Journal of Medical Research

Volumn 10, Issue 2, 2005, Pages 68-70

  Huber, Roman ^a   Futter, I ^a   Ludtke R ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Karl und Veronica Carstens Stiftung   (Germany)

Author keywords

Aminotransferase levels; Milk thistle; Silybin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; PEGINTERFERON; RIBAVIRIN; SILYMARIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEALTH CARE FACILITY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; MALE; PROTHROMBIN TIME; RETROSPECTIVE STUDY; SIDE EFFECT; STANDARDIZATION; STATISTICAL SIGNIFICANCE; SUPERINFECTION;

ADMINISTRATION, ORAL; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTECTIVE AGENTS; RETROSPECTIVE STUDIES; SILYMARIN;

EID: 14844286932     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Agoston M, Orsi F, Feher E, Hagymasi K, Orosz Z, Blazovics A, Feher J, Vereckei A (2003) Silymarin and vitamin E reduce amiodarone-induced lysosomal phospholipidosis in rats. Toxicology 190(3): 231-241
2. Bean P (2002) The use of alternative medicine in the treatment of hepatitis C. Am Clin Lab 21(4): 19-21
3. Barritta D, Jacobson IM, Esposito S, Russo MW (2001) The effect of milk thistle (Silymarin) on serum alanine aminotransferase and viral levels in patients with chronic hepatitis C. Am J Gastroenterol 96(9 Suppl.1): S 117
4. Boigk G, Stroedter L, Herbst H, Waldschmidt J, Riecken EO, Schuppan D (1997) Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 26(3): 643-649
5. Buzzelli G, Moscarella S, Giusti A, Duchini A, Marena C, Lampertico M (1993) A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB1016) in chronic active hepatitis. Int J Clin Pharmacol Ther Toxicol 31(9): 456-460
6. Diggle PJ, Liang KY, Zeger SL (1994) Analysis of Longitudinal Data. Clarendon, Press, Oxford.
7. Lee YS, Yoon SK, Chung ES, Bae SH, Choi JY, Han JY, Chung KW, Sun HS, Kim BS, Kim BK (2001) The relationship of histologic activity to serum ALT, HCV genotype and HCV RNA titers in chronic hepatitis C. J Korean Med Sci 16(5): 585-591
8. Liu JP, Manheimer E, Tsutani K, Gluud C (2001) Medicinal herbs for hepatitis C virus infection. Cochrane Database (4):CD003183
9. Mourelle M, Muriel P, Favari L, Franco T (1989) Prevention of CCL4-induced liver cirrhosis by silymarin. Fundam Clin Pharmacol 3(3): 183-191
10. Pradat P, Alberti A, Poynard T, Esteban JI, Weiland O, Marcellin P, Badalamenti S, Trepo C (2002) Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology. 36(4): 973-977
11. Saller R, Meier R, Brignoli R (2001) The use of silymarin in the treatment of liver diseases. Drugs 61(14): 2053-2063
12. Schulz HU, Schurer M, Krumbiegel G, Wachter W, Weyhenmeyer R, Seidel G (1995) The solubility and bioequivalence of silymarin preparations. Arzneimittelforschung/Drug Res 45(1): 61-64
13. Schwabe U, Paffrath D (2004) Arzneiverordnungs-Report 2003: aktuelle Daten, Kosten, Trends und Kommentare. Springer, Berlin
14. Schuppan D, Jia JD, Brinkhaus B, Hahn EG (1999) Herbal products for liver disease: a therapeutic challenge for the new millenium. Hepatology 30(4): 1099-104
15. Shiffman ML, Stewart CA, Hofmann CM, Contos MJ, Luketic VA, Sterling RK, Sanyal AJ (2000) Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology and response to interferon therapy. J Infect Dis 182(6): 1595-1601
16. Tyutyulkova N, Gorantcheva U, Tuneva S, Chelibonova-Lorer H, Gavasova E, Zhivkov V (1983) Effect of silymarin (Carsil) on the microsomal glycoprotein and protein biosynthesis in liver of rats with experimental galactosamine hepatitis. Methods Find Exp Clin Pharmacol 5(3): 181-184
17. Wellington K, Jarvis B (2001) Silymarin: a review of its clinical properties in the management of hepatic disorders. Biodrugs 15(7):465-489